AstraZeneca (AZN) Earnings Date & Reports

Key Takeaways

• Core EPS beat expectations: AstraZeneca reported Q2 2026 core earnings per share (EPS) of $2.63, surpassing analyst consensus estimates of approximately $2.48–$2.50 and rising 21% year-over-year on a reported basis.
• Revenue met forecasts: Total revenue reached $15.38 billion in the quarter, up 5% at constant exchange rates (CER), broadly in line with company-compiled consensus of $15.39 billion.
• Oncology and Rare Disease led growth: Oncology revenue jumped 15% in the first half to $14.1 billion, while Rare Disease rose 11% to $4.9 billion, offsetting generic competition for legacy products.
• Farxiga patent cliff weighed on results: Revenue from diabetes drug Farxiga fell 19% in Q2 following U.S. generic entry, and Brilinta declined 63%, dragging Biopharmaceuticals revenue down 5% in the first half.
• Full-year guidance reaffirmed: Management reiterated expectations for mid-to-high single-digit total revenue growth and low double-digit core EPS growth in 2026 at constant exchange rates.
• Dividend increased: The interim dividend was raised to $1.06 per share from $1.03 a year ago, signaling confidence in the company's financial position.

Earnings Context and Why It Matters

AstraZeneca's Q2 2026 results arrived at a pivotal moment. The company is navigating a transitional period defined by two opposing forces: accelerating growth in its oncology and rare disease franchises, and the loss of exclusivity (LOE) on blockbuster drugs Farxiga and Brilinta. This earnings report was the first full quarter to reflect the impact of U.S. generic competition for Farxiga, which had been one of AstraZeneca's largest revenue drivers. Meanwhile, investors were eager for management's response to the recent CARDIO-TTRansform trial failure for Wainua, which triggered a 10% single-day share price drop earlier in July. The Q2 print, therefore, served as a critical test of whether AstraZeneca's diversified portfolio and pipeline could absorb these setbacks while keeping its $80 billion 2030 revenue ambition on track.

Reported Results

AstraZeneca posted Q2 2026 total revenue of $15.38 billion, up 5% at constant exchange rates and broadly in line with the $15.39 billion company-compiled consensus. Product revenue, which excludes collaboration income, reached $30.6 billion in the first half, while alliance revenue surged 29% to $1.7 billion, reflecting higher profit shares from partnered medicines including Enhertu (developed with Daiichi Sankyo) and Tezspire (partnered with Amgen).

Core EPS of $2.63 for the quarter exceeded consensus estimates and represented 18% growth at constant currency. For the first half, core EPS rose 11% to $5.21. The core gross margin held firm at 83% for H1, with Q2 margins improving to 84%, aided by a favorable product mix shift toward higher-margin oncology and rare disease therapies.

On the product level, Calquence surpassed $1 billion in quarterly sales for the first time, growing 16%. Tagrisso generated $1.94 billion (up 6%), while Enhertu climbed 31% to $888 million. Imfinzi combined with Imjudo grew 25%. In Rare Disease, Ultomiris rose 12% and Strensiq jumped 36%. These gains helped cushion the 19% decline in Farxiga sales and the 63% drop in Brilinta revenue following generic launches in the U.S. and Europe.

AI Screener

For investors looking to identify opportunities in the pharmaceutical sector or broader markets following earnings events like AstraZeneca's, Tickeron's AI Screener offers a powerful solution. The AI Screener is an AI-driven stock and ETF discovery tool that enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. By leveraging AI-powered signals, the screener helps users efficiently pinpoint trade ideas, trending stocks, breakout candidates, and emerging market opportunities without the time-intensive process of manual screening. Whether you are tracking pharmaceutical stocks or scanning for momentum across sectors, the AI Screener can streamline your research workflow.

Market Reaction and Investor Sentiment

AstraZeneca shares rose approximately 1.2% to 2% in London and New York trading following the Q2 release, reflecting investor relief that core earnings exceeded expectations despite the top-line revenue miss relative to some analyst estimates. The stock had been under pressure heading into the report after the Wainua trial failure earlier in July erased roughly 10% of its market value in a single session. The results and management's confident tone on the earnings call appeared to stabilize sentiment. Investors took particular comfort in the strength of oncology growth, the pipeline progress (including six positive Phase III readouts and 30 major-market approvals since Q4 2025), and the reaffirmed 2026 guidance. However, the shares remain below their 52-week high of $212.71, suggesting lingering caution around pipeline execution risk and the pace of the post-LOE revenue transition.

Forward Outlook and Key Factors to Monitor

Looking ahead, AstraZeneca's investment case hinges on several interconnected factors. Management confirmed it expects more than 20 high-value clinical readouts over the next 18 months, including pivotal data for six new molecular entities in 2027. The success or failure of these trials will heavily influence the stock's trajectory, particularly as the company works to demonstrate that its $80 billion revenue target by 2030 is achievable through organic pipeline delivery rather than a single product or acquisition.

The launch trajectory of recently approved medicines will also be closely watched. Baxfendy, a first-in-class treatment for hypertension, received U.S. approval in May 2026, and management indicated that access should broaden over coming quarters. Additionally, the oral GLP-1 candidate elecoglipron has advanced into comprehensive Phase III programs for obesity and type 2 diabetes following positive Phase IIb data showing weight loss of up to 11.8% at 36 weeks. This asset represents one of AstraZeneca's most significant commercial opportunities but faces intense competition in a crowded metabolic drug landscape.

On the cost side, the company signaled that core gross margins may dip in the second half of the year due to seasonal demand patterns for lower-margin medicines. Operating expenses continued to rise, with core R&D and SG&A (selling, general, and administrative) both increasing 6% in the first half as AstraZeneca invests in its pipeline and commercial launches. Net debt also rose by approximately $3.5 billion during H1, partly reflecting a $1.2 billion upfront payment for the CSPC collaboration and dividend distributions.

Finally, the China market remains a wildcard. Revenue growth in China was constrained by volume-based procurement (VBP) policies, but recent additions to the National Reimbursement Drug List and new regulatory approvals could support a recovery in future quarters. Investors should monitor how geopolitical and regulatory dynamics in China evolve and whether they materially affect AstraZeneca's emerging market growth strategy.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations